Clinical Behavior of Breast Cancer in Young BRCA Carriers and Prediagnostic Awareness of Germline BRCA Status

Authors: Matteo Lambertini, Eva Blondeaux, Loredana M. Tomasello, Elisa Agostinetto, Anne-Sophie Hamy, Hee Jeong Kim, Maria Alice Franzoi, Rinat Bernstein-Molho, Florentine Hilbers, Katarzyna Pogoda, Hans Wildiers, Jyoti Bajpai, Michail Ignatiadis, Halle C.F. Moore, Ann H. Partridge, Kelly-Anne Phillips, Angela Toss, Christine Rousset-Jablonski, Carmen Criscitiello, Tiphaine Renaud, Alberta Ferrari, Shani Paluch-Shimon, Robert Fruscio, Wanda Cui, Stephanie M. Wong, Claudio Vernieri, Kathryn J. Ruddy, Maria Vittoria Dieci, Alexios Matikas, Mariya Rozenblit, Cynthia Villarreal-Garza, Laura De Marchis, Fabio Puglisi, Kenny A. Rodriguez-Wallberg, Francois P. Duhoux, Luca Livraghi, Marco Bruzzone, Luca Boni, Judith Balmaña

Contributors: Institut Català de la Salut, [Lambertini M] Department of Internal Medicine and Medical Specialties (DIMI), School of Medicine, University of Genova, Genoa, Italy. Medical Oncology Department, U.O.C. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genoa, Italy. [Blondeaux E] U. O. Epidemiologia Clinica, IRCCS Ospedale Policlinico San Martino, Genoa, Italy. [Tomasello LM] Department of Internal Medicine and Medical Specialties (DIMI), School of Medicine, University of Genova, Genoa, Italy. Section of Medical Oncology, Department of Precision Medicine in Medical, Surgical and Clinical Care (Me.Pre.C.C), University of Palermo, Palermo, Italy. [Agostinetto E] Medical Oncology Department, Institut Jules Bordet, Université Libre de Bruxelles (U.L.B.), Hôpital Universitaire de Bruxelles (HUB), Brussels, Belgium. [Hamy AS] Department of Medical Oncology, Université Paris Cite, Institut Curie, Paris, France. [Kim HJ] Division of Breast Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. [Balmaña J] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Hereditary Cancer Genetics Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie

Source: J Clin Oncol
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 2025, no.2025, p. JCO2401334 (2025)

Subject Terms: brca, young, clinical, breast cancer, Adult, PHENOMENA AND PROCESSES::Genetic Phenomena::Genetic Variation::Mutation::Germ-Line Mutation, Heterozygote, CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Fanconi Anemia Complementation Group Proteins::BRCA1 Protein, BRCA, Breast Neoplasms, MUTATION CARRIERS, Other subheadings::Other subheadings::/diagnosis, Young Adult, AGE, Mama - Càncer - Propensió, Otros calificadores::Otros calificadores::/diagnóstico, 3211 Oncology and carcinogenesis, Humans, Genetic Predisposition to Disease, 1112 Oncology and Carcinogenesis, Genetic Testing, Oncology & Carcinogenesis, Mama - Càncer - Diagnòstic, Germ-Line Mutation, Retrospective Studies, RISK, BRCA2 Protein, Science & Technology, INTERNATIONAL CONSENSUS GUIDELINES, ENFERMEDADES::afecciones patológicas, signos y síntomas::procesos patológicos::atributos de la enfermedad::susceptibilidad a enfermedades::predisposición genética a la enfermedad, BRCA1 Protein, WOMEN, 1103 Clinical Sciences, ORIGINAL REPORTS, OVARIAN, Prognosis, DISEASES::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Disease Attributes::Disease Susceptibility::Genetic Predisposition to Disease, Anomalies cromosòmiques, Oncology, FENÓMENOS Y PROCESOS::fenómenos genéticos::variación genética::mutación::mutación de la línea germinal, Mama - Càncer - Aspectes genètics, Female, COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas de grupos de complementación de la anemia de Fanconi::proteína BRCA1, Life Sciences & Biomedicine, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama, DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/39993249
http://hdl.handle.net/11351/13353
https://hdl.handle.net/10281/548483
https://doi.org/10.1200/JCO-24-01334
https://hdl.handle.net/2078.1/299868

TUXEDO-4: phase II study of trastuzumab-deruxtecan in HER2-low breast cancer with new or progressing brain metastases

Authors: Marhold, Maximilian, Vaz Batista, Marta, Blancas, Isabel, Morales, Cristina, Saura-Manich, Cristina, Saavedra, Cristina, Ruíz-Borrego, Manuel, Cortez, Patricia, Slebe, Felipe, Campolier, Marta, Santos, Juliana Carvalho, Guerrero-Martínez, José Antonio, Jiménez-Cortegana, Carlos, Rottenmanner, Beate, Forstner, Heidrun, Bartsch, Rupert, Preusser, Matthias

Contributors: Institut Català de la Salut, [Marhold M] Department of Medicine 1, Division of Oncology, Medical University of Vienna, Vienna, Austria. [Vaz Batista M] Department of Oncology, Hospital Professor Doutor Fernando Fonseca EPE, Lisbon, Portugal. Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain. [Blancas I] Department of Oncology, Hospital Universitario Clínico San Cecilio, Granada, Spain. Medicine Department, University of Granada, Granada, Spain. Área de Oncología Instituto de Investigación Biosanitaria de Granada, Granada, Spain. [Morales C] Servicio de Oncología Médica, Hospital Universitario Reina Sofía, Córdoba, Spain. [Saura-Manich C] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Saavedra C] Departamento de Oncología Médica, Hospital Universitario Ramón y Cajal, Madrid, Spain. IOB Madrid, Institute of Oncology, Hospital Beata María Ana, Madrid, Spain, Vall d'Hebron Barcelona Hospital Campus

Source: Future Oncol
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname

Subject Terms: Adult, Clinical Trial Protocol, Immunoconjugates, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, Receptor, ErbB-2, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols, DISEASES::Neoplasms::Neoplasms by Site::Nervous System Neoplasms::Central Nervous System Neoplasms::Brain Neoplasms, Breast Neoplasms, COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::globulinas séricas::inmunoglobulinas::anticuerpos::inmunoconjugados, Quimioteràpia combinada, Clinical Trials, Phase II as Topic, Metàstasi, Antineoplastic Combined Chemotherapy Protocols, Humans, CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Serum Globulins::Immunoglobulins::Antibodies::Immunoconjugates, ENFERMEDADES::neoplasias::procesos neoplásicos::metástasis neoplásica, Aged, Other subheadings::Other subheadings::Other subheadings::/drug therapy, Anticossos monoclonals - Ús terapèutic, Brain Neoplasms, Trastuzumab, Middle Aged, DISEASES::Neoplasms::Neoplastic Processes::Neoplasm Metastasis, Treatment Outcome, Cervell - Càncer - Tractament, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema nervioso::neoplasias del sistema nervioso central::neoplasias cerebrales, Mama - Càncer - Tractament, Disease Progression, Female, Camptothecin, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama, DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/40018758
http://hdl.handle.net/11351/12967

New Oral Selective Estrogen Receptor Degraders Redefine Management of Estrogen Receptor–Positive Breast Cancer

Authors: Pathak, Neha, Oliveira, Mafalda

Contributors: Institut Català de la Salut, [Pathak N] Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Center, University of Toronto, Toronto, Canada. [Oliveira M] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Breast Cancer Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

Source: Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname

Subject Terms: COMPUESTOS QUÍMICOS Y DROGAS::hormonas, sustitutos de hormonas y antagonistas de hormonas::antagonistas de hormonas::antagonistas de estrógenos::antagonistas de receptores estrogénicos, Selective Estrogen Receptor Modulators, CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents::Antineoplastic Agents, Hormonal, Other subheadings::Other subheadings::Other subheadings::/drug therapy, COMPUESTOS QUÍMICOS Y DROGAS::hormonas, sustitutos de hormonas y antagonistas de hormonas::antagonistas de hormonas::moduladores de los receptores de estrógenos::moduladores selectivos de los receptores de estrógenos, COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos::antineoplásicos hormonales, Antineoplastic Agents, Hormonal, Other subheadings::Other subheadings::/therapeutic use, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, Estrògens - Antagonistes - Ús terapèutic, Otros calificadores::Otros calificadores::/uso terapéutico, Medicaments antineoplàstics - Ús terapèutic, Administration, Oral, Breast Neoplasms, Antihormones - Ús terapèutic, CHEMICALS AND DRUGS::Hormones, Hormone Substitutes, and Hormone Antagonists::Hormone Antagonists::Estrogen Antagonists::Estrogen Receptor Antagonists, Receptors, Estrogen, Mama - Càncer - Tractament, Humans, Female, Estrogen Receptor Antagonists, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama, CHEMICALS AND DRUGS::Hormones, Hormone Substitutes, and Hormone Antagonists::Hormone Antagonists::Estrogen Receptor Modulators::Selective Estrogen Receptor Modulators, DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/39869433
http://hdl.handle.net/11351/12794

Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study

Authors: Komal L. Jhaveri, Elgene Lim, Rinath Jeselsohn, Cynthia X. Ma, Erika P. Hamilton, Cynthia Osborne, Manali Bhave, Peter A. Kaufman, J. Thaddeus Beck, Luis Manso Sanchez, Ritesh Parajuli, Hwei-Chung Wang, Jessica J. Tao, Seock-Ah Im, Kathleen Harnden, Kan Yonemori, Ajay Dhakal, Patrick Neven, Philippe Aftimos, Jean-Yves Pierga, Yen-Shen Lu, Timothy Larson, Yolanda Jerez, Kostandinos Sideras, Joohyuk Sohn, Sung-Bae Kim, Cristina Saura, Aditya Bardia, Sarah L. Sammons, Francesca Bacchion, Yujia Li, Eunice Yuen, Shawn T. Estrem, Vanessa Rodrik-Outmezguine, Bastien Nguyen, Roohi Ismail-Khan, Lillian Smyth, Muralidhar Beeram

Contributors: Institut Català de la Salut, [Jhaveri KL] Memorial Sloan Kettering Cancer Center, New York, NY. Weill Cornell Medical College, New York, NY. Weill Cornell Medical College, New York, NY. [Lim E] Garvan Institute of Medical Research, St Vincent’s Clinical School, University of New South Wales, Darlinghurst, NSW, Australia. [Jeselsohn R] Dana-Farber Cancer Institute, Boston, MA. [Ma CX] Washington University School of Medicine, St Louis, MO. [Hamilton EP] Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN. [Osborne C] US Oncology Research, McKesson Specialty Health, The Woodlands, TX. Texas Oncology, Baylor-Sammons Cancer Center, Dallas, TX. [Saura C] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

Source: J Clin Oncol
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname

Subject Terms: Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada, Receptor, ErbB-2, ABEMACICLIB, Aminopyridines, Administration, Oral, ALPELISIB PLUS FULVESTRANT, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Drug Therapy::Molecular Targeted Therapy, DOUBLE-BLIND, ErbB-2, MONARCH 2, Receptors, Antineoplastic Combined Chemotherapy Protocols, 80 and over, Medicine and Health Sciences, Molecular Targeted Therapy, Aged, 80 and over, Other subheadings::Other subheadings::Other subheadings::/drug therapy, Aromatase Inhibitors, WOMEN, ORIGINAL REPORTS, Middle Aged, Progression-Free Survival, Oncology, Receptors, Estrogen, GUIDELINE, Administration, Female, Life Sciences & Biomedicine, Receptor, Oral, Adult, ESR1 MUTATIONS, Receptor, erbB-2, EXEMESTANE, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::farmacoterapia::terapia molecular selectiva, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Quimioteràpia combinada, ANASTROZOLE, 3211 Oncology and carcinogenesis, Humans, 1112 Oncology and Carcinogenesis, Oncology & Carcinogenesis, Everolimus, Aged, Science & Technology, ICTS (Institute of Clinical and Translational Sciences), Cyclin-Dependent Kinase 4, 1103 Clinical Sciences, Estrogen, Thiazoles, Mama - Càncer - Tractament, Mama - Càncer - Aspectes genètics, Benzimidazoles, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama, DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/39241211
https://hdl.handle.net/11351/12358

Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA -Mutated, Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced or Metastatic Breast Cancer

Authors: Komal L. Jhaveri, Melissa K. Accordino, Philippe L. Bedard, Andrés Cervantes, Valentina Gambardella, Erika Hamilton, Antoine Italiano, Kevin Kalinsky, Ian E. Krop, Mafalda Oliveira, Peter Schmid, Cristina Saura, Nicholas C. Turner, Andrea Varga, Sravanthi Cheeti, Stephanie Hilz, Katherine E. Hutchinson, Yanling Jin, Stephanie Royer-Joo, Ubong Peters, Noopur Shankar, Jennifer L. Schutzman, Dejan Juric

Contributors: Institut Català de la Salut, [Jhaveri KL] Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY. [Accordino MK] Columbia University Irving Medical Center, New York, NY. [Bedard PL] Princess Margaret Cancer Centre—University Health Network, University of Toronto, Toronto, ON, Canada. [Cervantes A, Gambardella V] Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain. CIBERONC, Instituto de Salud Carlos III, Madrid, Spain. [Hamilton E] Sarah Cannon Research Institute, Nashville, TN. [Oliveira M, Saura C] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus, Turner, Nicholas

Source: J Clin Oncol
JOURNAL OF CLINICAL ONCOLOGY
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
Consejo Superior de Investigaciones Científicas (CSIC)
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname

Subject Terms: Adult, 0301 basic medicine, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, Class I Phosphatidylinositol 3-Kinases, Pyridines, Receptor, ErbB-2, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Piperazines, 03 medical and health sciences, ErbB-2, 0302 clinical medicine, Receptors, Antineoplastic Combined Chemotherapy Protocols, 80 and over, Humans, Fulvestrant, Progesterone, Aged, Aged, 80 and over, FENÓMENOS Y PROCESOS::fenómenos genéticos::variación genética::mutación, Other subheadings::Other subheadings::Other subheadings::/drug therapy, ORIGINAL REPORTS, Middle Aged, Estrogen, Anomalies cromosòmiques, Receptors, Estrogen, PHENOMENA AND PROCESSES::Genetic Phenomena::Genetic Variation::Mutation, Mama - Càncer - Tractament, Mutation, Letrozole, Mama - Càncer - Aspectes genètics, Female, Receptors, Progesterone, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama, DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms, Receptor

File Description: application/pdf; Print-Electronic

Access URL: https://pubmed.ncbi.nlm.nih.gov/39236276
https://incliva.fundanetsuite.com/publicaciones/ProdCientif/PublicacionFrw.aspx?id=18676
https://hdl.handle.net/11351/12263

Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT

Authors: Paolo Tarantino, Nabihah Tayob, Guillermo Villacampa, Chau Dang, Denise A. Yardley, Steven J. Isakoff, Vicente Valero, Meredith Faggen, Therese Mulvey, Ron Bose, Douglas Weckstein, Antonio C. Wolff, Katherine Reeder-Hayes, Hope S. Rugo, Bhuvaneswari Ramaswamy, Dan Zuckerman, Lowell Hart, Vijayakrishna K. Gadi, Michael Constantine, Kit Cheng, Audrey Merrill Garrett, P. Kelly Marcom, Kathy Albain, Patricia DeFusco, Nadine Tung, Blair Ardman, Rita Nanda, Rachel C. Jankowitz, Mothaffar Rimawi, Vandana Abramson, Paula R. Pohlmann, Catherine Van Poznak, Andres Forero-Torres, Minetta C. Liu, Kathryn J. Ruddy, Adrienne G. Waks, Michelle DeMeo, Harold J. Burstein, Ann H. Partridge, Patrizia Dell'Orto, Leila Russo, Emma Krause, Daniel J. Newhouse, Busem Binboğa Kurt, Elizabeth A. Mittendorf, Bryan Schneider, Aleix Prat, Eric P. Winer, Ian E. Krop, Sara M. Tolaney, Romualdo Barroso-Sousa, Giuseppe Curigliano, Molly DiLullo, Winnie Hui, Christian Kirkup, Giuseppe Viale, Yue Zheng

Contributors: Institut Català de la Salut, [Tarantino P] Medical Oncology, Dana-Farber Cancer Institute, Boston, MA. Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA. Harvard Medical School, Boston, MA. Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. [Tayob N] Harvard Medical School, Boston, MA. Division of Data Science, Dana-Farber Cancer Institute, Boston, MA. [Villacampa G] SOLTI Breast Cancer Research Group, Barcelona, Spain. Oncology Data Science Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Dang C] Memorial Sloan Kettering Cancer Center, New York, NY. [Yardley DA] Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN. [Isakoff SJ] Harvard Medical School, Boston, MA. Massachusetts General Hospital, Boston, MA, Vall d'Hebron Barcelona Hospital Campus

Source: J Clin Oncol
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname
Journal of Clinical Oncology, vol 42, iss 31

Subject Terms: Adult, 0301 basic medicine, Paclitaxel, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, Receptor, ErbB-2, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Ado-Trastuzumab Emtansine, Quimioteràpia combinada, Disease-Free Survival, 03 medical and health sciences, ErbB-2, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, Medicine and Health Sciences, Chemotherapy, Humans, Adjuvant, Neoplasm Staging, Aged, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome::Disease-Free Survival, Other subheadings::Other subheadings::Other subheadings::/drug therapy, ICTS (Institute of Clinical and Translational Sciences), ORIGINAL REPORTS, Middle Aged, Trastuzumab, Chemotherapy, Adjuvant, Mama - Càncer - Tractament, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento::supervivencia sin enfermedad, Avaluació de resultats (Assistència sanitària), Female, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama, DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms, Receptor

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/38935923
https://hdl.handle.net/11351/12237
https://escholarship.org/uc/item/7q88c66q
https://escholarship.org/content/qt7q88c66q/qt7q88c66q.pdf

Population-based germline breast cancer gene association studies and meta-analysis to inform wider mainstream testing

Authors: Rowlands, CF, Allen, S, Balmaña, J, Domchek, SM, Evans, DG, Hanson, H, Hoogerbrugge, N, James, PA, Nathanson, KL, Robson, M, Tischkowitz, M, Foulkes, WD, Turnbull, C

Contributors: Institut Català de la Salut, [Rowlands CF, Allen S] Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK. [Balmaña J] Hereditary Cancer Genetics Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Domchek SM] Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA. [Evans DG] Manchester Academic Health Science Centre, Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK. [Hanson H] Department of Clinical and Biomedical Sciences, University of Exeter Medical School, Exeter, UK. Peninsula Regional Genetics Service, Royal Devon University Healthcare NHS Foundation Trust, Exeter, UK, Vall d'Hebron Barcelona Hospital Campus, Allen, Sophie, Turnbull, Clare

Source: Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname
Annals of Oncology, 35, 10, pp. 892-901
Allen, S, Balmaña, J, Domchek, S M, Evans, D G, Hoogerbrugge, N, Nathanson, K L, Tischkowitz, M, Foulkes, W D & Turnbull, C 2024, 'Population-based germline breast cancer gene association studies and meta-analysis to inform wider mainstream testing', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 35, no. 10, pp. 892-901. https://doi.org/10.1016/j.annonc.2024.07.244

Subject Terms: Other subheadings::Other subheadings::Other subheadings::/genetics, Ubiquitin-Protein Ligases, Breast Neoplasms, Ataxia Telangiectasia Mutated Proteins, Breast Neoplasms/genetics, Checkpoint Kinase 2/genetics, breast cancer, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Diagnostic Techniques and Procedures::Clinical Laboratory Techniques::Genetic Testing, Ataxia Telangiectasia Mutated Proteins/genetics, Otros calificadores::Otros calificadores::Otros calificadores::/genética, Humans, Genetic Predisposition to Disease, Ubiquitin-Protein Ligases/genetics, Genetic Testing, Germ-Line Mutation, Genetic Association Studies, BRCA2 Protein, BRCA1 Protein, Tumor Suppressor Proteins, mainstream genetic testing, Cromosomes humans - Anomalies - Diagnòstic, Fanconi Anemia Complementation Group N Protein/genetics, BRCA2 Protein/genetics, 3. Good health, DNA-Binding Proteins, Meta-analysis, Checkpoint Kinase 2, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::técnicas y procedimientos diagnósticos::técnicas de laboratorio clínico::pruebas genéticas, Case-Control Studies, multi-gene panel testing, BRCA1 Protein/genetics, Mama - Càncer - Aspectes genètics, Human Genetics - Radboud University Medical Center, Female, Fanconi Anemia Complementation Group N Protein, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama, case-control, DNA-Binding Proteins/genetics, Genetic Testing/methods, DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms

File Description: application/pdf; Print-Electronic

Access URL: https://pubmed.ncbi.nlm.nih.gov/38986768
https://hdl.handle.net/11351/11965
https://research.manchester.ac.uk/en/publications/590e571d-7ad9-4fb3-b723-57aaa7277a35
https://doi.org/10.1016/j.annonc.2024.07.244
https://repository.ubn.ru.nl/handle/2066/310405
https://repository.ubn.ru.nl//bitstream/handle/2066/310405/310405.pdf
https://research.manchester.ac.uk/en/publications/590e571d-7ad9-4fb3-b723-57aaa7277a35
http://www.scopus.com/inward/record.url?scp=85201586788&partnerID=8YFLogxK
https://doi.org/10.1016/j.annonc.2024.07.244

Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial: a phase 3b/4 trial

Authors: Harbeck, Nadia, Ciruelos, Eva, Jerusalem, Guy, Mueller, Volkmar, Niikura, Naoki, Viale, Giuseppe, Bartsch, Rupert, Kurzeder, Christian, Higgins, Michaela J., Connolly, Roisin M., Baron-Hay, Sally, Gion, Maria, Guarneri, Valentina, Bianchini, Giampaolo, Wildiers, Hans, Escriva-de-Romani, Santiago, Prahladan, Manoj, Bridge, Helen, Kuptsova-Clarkson, Nataliya, Scotto, Nana, Verma, Sunil, Lin, Nancy U., Yeo, Belinda, Mccarthy, Nicole, Mccartney, Amelia, Clay, Timothy, Murray, Nicholas, Gombos, Andrea, Collignon, Joelle, De Cuypere, Eveline, Jerzak, Katarzyna, Chia, Stephen, Maraldo, Maja, Ronlev, Jeanette, Brix, Eva, Tanner, Minna, Mattson, Johanna, Huovinen, Riikka, Wimberger, Pauline, Reinisch, Mattea, Tesch, Hans, Untch, Michael, Fasching, Peter, Park-Simon, Tjoung-Won, Tio, Joke, Braun, Michael, Grischke, Eva Maria, Marme, Frederik, van Mackelenbergh, Marion, Mccaffrey, John, De Laurentiis, Michelino, Caruso, Michele, Berardi, Rossana, Biganzoli, Laura, Fotia, Vittoria, Yamashita, Toshinari, Tsurutani, Junji, Tsugawa, Koichiro, Tomioka, Nobumoto, de Boer, Maaike, Houtsma, Daniel, Pilskog, Martin, Engebraten, Olav, Saetersdal, Anna, Wysocki, Piotr, Nowecki, Zbigniew, Radecka, Barbara, Jassem, Jacek, Duchnowska, Renata, Simoes, Joana, Cardoso, Fatima, Sousa, Ana Rita, Losada, Maria Jesus Vidal, Manich, Cristina Saura, Gregori, Joaquin Gavila, Marti, Maria Pilar Lopez, Borrego, Manuel Ruiz, Castan, Javier Cortes, Lopez, Rafael Lopez, Sanchez, Cesar Rodriguez, Flores, Encarnacion Gonzalez, Gonzalez, Carmen Hinojo, del Prado, Purificacion Martinez, Schiza, Aglaia, Killander, Fredrika, Klint, Leif, Rossi, Lorenzo, Aebi, Stefan, Zaman, Khalil, Hall, Peter, Anders, Carey

Contributors: Institut Català de la Salut, [Harbeck N] Breast Center, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Munich, LMU University Hospital, Munich, Germany. [Ciruelos E] Hospital Universitario 12 de Octubre, Madrid, Spain. [Jerusalem G] CHU Liège and Liège University, Liège, Belgium. [Müller V] University Medical Center Hamburg-Eppendorf, Hamburg, Germany. [Niikura N] Tokai University School of Medicine, Kanagawa, Japan. [Viale G] Department of Pathology and Laboratory Medicine, IEO European Institute of Oncology IRCCS, Milan, Italy. [Escrivá-de-Romaní S] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

Source: Nat Med
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname

Subject Terms: Immunoconjugates, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, Receptor, ErbB-2, Oncologie, Medicaments antineoplàstics - Ús terapèutic, Research & Experimental Medicine, DESTINY-Breast12 study group, Antineoplastic Agents, Immunological, COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos::inmunoterapia antineoplásica, Immunoconjugates/adverse effects, Prospective Studies, Human health sciences, 11 Medical and Health Sciences, EXPLORATORY ANALYSIS, CLINICAL-PRACTICE GUIDELINE, Other subheadings::Other subheadings::Other subheadings::/drug therapy, Anticossos monoclonals - Ús terapèutic, Brain Neoplasms, CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal, Middle Aged, Progression-Free Survival, trastuzumab deruxtecan, EMTANSINE T-DM1, Oncology, Medicine, Research & Experimental, ErbB-2/metabolism, Female, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento::supervivencia libre de progresión, Life Sciences & Biomedicine, Receptor, RADIOTHERAPY, RADIOSURGERY, Adult, Biochemistry & Molecular Biology, Receptor, erbB-2, Immunology, SOCIETY, Antineoplastic Agents, Brain Neoplasms/drug therapy, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome::Progression-Free Survival, Breast Neoplasms, CAPECITABINE, Sciences de la santé humaine, Article, Immunological/therapeutic use, Breast Neoplasms/drug therapy, COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales, CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents::Antineoplastic Agents, Immunological, Humans, Immunoconjugates/therapeutic use, Aged, Trastuzumab/therapeutic use, Science & Technology, 42 Health sciences, ERBB2 protein, human, Cell Biology, 32 Biomedical and clinical sciences, Trastuzumab, EFFICACY, DS-8201A, Mama - Càncer - Tractament, Avaluació de resultats (Assistència sanitària), Brain Neoplasms/secondary, Camptothecin/analogs & derivatives, Camptothecin, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama, DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/39271844
https://hdl.handle.net/11351/12359
https://cris.maastrichtuniversity.nl/en/publications/5907550f-729b-40c9-900e-d22721072849
https://doi.org/10.1038/s41591-024-03261-7
https://www.nature.com/articles/s41591-024-03261-7#article-info
https://doi.org/10.1038/s41591-024-03261-7
https://hdl.handle.net/20.500.11768/172577
https://www.nature.com/articles/s41591-024-03261-7
https://doi.org/10.1038/s41591-024-03261-7
https://lirias.kuleuven.be/handle/20.500.12942/750006
https://doi.org/10.1038/s41591-024-03261-7
https://hdl.handle.net/2268/328027
https://doi.org/10.1038/s41591-024-03261-7
https://portal.findresearcher.sdu.dk/da/publications/06812573-f19e-46ad-8295-e6fc0b9f1d28
https://doi.org/10.1038/s41591-024-03261-7

ERK1/2 mitogen‐activated protein kinase dimerization is essential for the regulation of cell motility

Authors: Dalia de la Fuente‐Vivas, Vincenzo Cappitelli, Rocío García‐Gómez, Sara Valero‐Díaz, Camilla Amato, Javier Rodriguéz, Santiago Duro‐Sánchez, Alexander von Kriegsheim, Michael Grusch, José Lozano, Joaquín Arribas, Berta Casar, Piero Crespo

Contributors: Hospital Universitari Vall d'Hebron, Institut Català de la Salut, [de la Fuente-Vivas D, Cappitelli V, Valero-Díaz S, Amato C] Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), Consejo Superior de Investigaciones Científicas (CSIC) – Universidad de Cantabria, Santander, Spain. [García-Gómez R] Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), Consejo Superior de Investigaciones Científicas (CSIC) – Universidad de Cantabria, Santander, Spain. Centro de Investigacion Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain. [Rodriguéz J] Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, UK. [Duro-Sánchez S, Arribas J] Centro de Investigacion Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain. Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain. Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona, Bellaterra, Spain. Preclinical and Translational Research Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus, Universidad de Cantabria

Source: Mol Oncol
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname
Molecular Oncology, Vol 19, Iss 2, Pp 452-473 (2025)

Subject Terms: Other subheadings::Other subheadings::Other subheadings::/genetics, CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Amino Acids, Peptides, and Proteins::Proteins::Intracellular Signaling Peptides and Proteins::Mitogen-Activated Protein Kinases::Extracellular Signal-Regulated MAP Kinases::Mitogen-Activated Protein Kinase 1, KSR, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Cell motility, cell motility, Cèl·lules - Motilitat, FENÓMENOS Y PROCESOS::fenómenos fisiológicos celulares::movimiento celular, PHENOMENA AND PROCESSES::Cell Physiological Phenomena::Cell Movement, ERK, scaffold proteins, COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::aminoácidos, péptidos y proteínas::proteínas::péptidos y proteínas de señalización intracelular::proteínas cinasas activadas por mitógenos::cinasas MAP reguladas por señales extracelulares::proteína cinasa activada por mitógenos 1, MAP kinases, Proteïnes quinases activades per mitògens, Otros calificadores::Otros calificadores::Otros calificadores::/genética, Scaffold proteins, Mama - Càncer - Aspectes genètics, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama, RC254-282, DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms, Research Article

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/39263917
http://hdl.handle.net/11351/12701
https://doaj.org/article/88947603665a4e1eae2593946fc70db4
https://hdl.handle.net/10902/36664

Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers

Authors: L. Arecco, M. Bruzzone, R. Bas, H.J. Kim, A. Di Meglio, R. Bernstein-Molho, F.S. Hilbers, K. Pogoda, E. Carrasco, K. Punie, J. Bajpai, E. Agostinetto, N. Lopetegui-Lia, A.H. Partridge, K.A. Phillips, A. Toss, C. Rousset-Jablonski, G. Curigliano, T. Renaud, A. Ferrari, S. Paluch-Shimon, R. Fruscio, W. Cui, S.M. Wong, C. Vernieri, F.J. Couch, M.V. Dieci, A. Matikas, M. Rozenblit, D. Aguilar-y Méndez, L. De Marchis, F. Puglisi, A. Fabi, S.L. Graff, I. Witzel, A. Rodriguez Hernandez, A. Fontana, R. Pesce, R. Duchnowska, H.L. Pais, V. Sini, E. Sokolović, E. de Azambuja, M. Ceppi, E. Blondeaux, M. Lambertini

Contributors: Institut Català de la Salut, [Arecco L] Department of Internal Medicine and Medical Specialties (DIMI), School of Medicine, University of Genova, Genova, Italy. Université libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Academic Trials Promoting Team, Bruxelles, Belgium. [Bruzzone M] U.O. Epidemiologia Clinica, IRCCS Ospedale Policlinico San Martino, Genova, Italy. [Bas R] Department of Surgery, Universite Paris Cité, Institut Curie, Paris, France. [Kim HJ] Division of Breast Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. [Di Meglio A] Cancer Survivorship Program—Molecular Predicitors and New Targets in Oncology, INSERM Unit 981, Gustave Roussy, Villejuif, France. [Bernstein-Molho R] Susanne Levy Gertner Oncogenetics Unit, The Danek Gertner Institute of Human Genetics, Chaim Sheba Medical Center Affiliated to Tel Aviv University, Tel Hashomer, Israel. [Carrasco E] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Hereditary Cancer Genetics Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

Source: Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname

Subject Terms: Adult, Mama - Càncer - Prognosi, Heterozygote, Other subheadings::Other subheadings::Other subheadings::/genetics, Receptor, ErbB-2, Breast Neoplasms, Disease-Free Survival, Young Adult, BRCA, early breast cancer, hormone receptor status, tumor subtypes, young patients, FENÓMENOS Y PROCESOS::fenómenos genéticos::estructuras genéticas::genoma::componentes genómicos::genes::genes de neoplasias::genes supresores de tumores::genes BRCA1, Otros calificadores::Otros calificadores::Otros calificadores::/genética, Biomarkers, Tumor, Humans, Germ-Line Mutation, Retrospective Studies, BRCA2 Protein, Gens del càncer, FENÓMENOS Y PROCESOS::fenómenos genéticos::variación genética::mutación, BRCA1 Protein, Prognosis, Anomalies cromosòmiques, PHENOMENA AND PROCESSES::Genetic Phenomena::Genetic Structures::Genome::Genome Components::Genes::Genes, Neoplasm::Genes, Tumor Suppressor::Genes, BRCA1, Receptors, Estrogen, PHENOMENA AND PROCESSES::Genetic Phenomena::Genetic Variation::Mutation, Mama - Càncer - Aspectes genètics, Female, Receptors, Progesterone, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama, DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/38908482
https://hdl.handle.net/11351/11987
https://hdl.handle.net/2434/1115453
https://doi.org/10.1016/j.annonc.2024.06.009
https://hdl.handle.net/10281/500459
https://doi.org/10.1016/j.annonc.2024.06.009
https://hdl.handle.net/11380/1367654
https://doi.org/10.1016/j.annonc.2024.06.009
https://hdl.handle.net/11573/1716962
https://hdl.handle.net/11573/1721075
https://doi.org/10.1016/j.annonc.2024.06.009

A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results

Authors: Hamilton, E, Oliveira, M, Turner, N, García-Corbacho, J, Hernando, C, Ciruelos, EM, Kabos, P, Ruiz-Borrego, M, Armstrong, A, Patel, MR, Vaklavas, C, Twelves, C, Boni, V, Incorvati, J, Brier, T, Gibbons, L, Klinowska, T, Lindemann, JPO, Morrow, CJ, Sykes, A, Baird, RD

Contributors: Institut Català de la Salut, [Hamilton E] Sarah Cannon Research Institute, Nashville, USA. [Oliveira M] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Breast Cancer Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Turner N] Breast Cancer Now, Toby Robins Research Centre, Institute of Cancer Research, London, UK. [García-Corbacho J] ICMHO Clinical Trials Unit, Hospital Clinic, Barcelona. [Hernando C] Department of Medical Oncology, Hospital Clinico Universitario de Valencia, Biomedical Research Institute (INCLIVA), Valencia. [Ciruelos EM] Medical Oncology Department, 12 de Octubre University Hospital, Madrid, Spain, Vall d'Hebron Barcelona Hospital Campus, DSpace at Cambridge pro (8.1)

Source: Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname
ANNALS OF ONCOLOGY
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA

Subject Terms: Adult, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Toxicity Tests::Maximum Tolerated Dose, Maximum Tolerated Dose, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, Receptor, ErbB-2, Medicació oral, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::pruebas de toxicidad::dosis máxima tolerada, Administration, Oral, Breast Neoplasms, CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Receptors, Cytoplasmic and Nuclear::Receptors, Steroid::Receptors, Estrogen, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::farmacoterapia::vías de administración de medicamentos::administración oral, ER+ HER2- breast cancer, Humans, Aged, Aged, 80 and over, Other subheadings::Other subheadings::Other subheadings::/drug therapy, Dose-Response Relationship, Drug, next-generation oral SERD, Estrogen Receptor alpha, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Drug Therapy::Drug Administration Routes::Administration, Oral, Middle Aged, Isoquinolines, Posologia, 3. Good health, Estrògens - Receptors, Receptors, Estrogen, Mama - Càncer - Tractament, Azetidines, camizestrant, Female, COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::receptores citoplásmicos y nucleares::receptores de esteroides::receptores de estrógenos, ER+ HER2− breast cancer, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama, DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/38729567
https://hdl.handle.net/11351/11845
https://incliva.fundanetsuite.com/publicaciones/ProdCientif/PublicacionFrw.aspx?id=18597
https://www.repository.cam.ac.uk/handle/1810/369586
https://doi.org/10.1016/j.annonc.2024.04.012
https://doi.org/10.17863/cam.109325

Adverse events and impact on quality of life of antibody‐drug conjugates in the treatment of metastatic breast cancer: A systematic review and meta‐analysis

Authors: Marta Perachino, Eva Blondeaux, Chiara Molinelli, Tommaso Ruelle, Irene Giannubilo, Luca Arecco, Simone Nardin, Maria Grazia Razeti, Roberto Borea, Diletta Favero, Chiara Lanzavecchia, Edoardo Chiappe, Loredana Tomasello, Elene Mariamidze, Kristina Jankovic, Mihaela Stana, Silvia Ottonello, Graziana Scavone, Luciana de Moura Leite, Stefano Spinaci, Cristina Saura, Matteo Lambertini

Contributors: Institut Català de la Salut, [Perachino M] U.O. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genoa, Italy. Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genoa, Italy. Servei d’Oncologia Mèdica, Vall d’Hebron Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Blondeaux E] U. O. Epidemiologia Clinica, IRCCS Ospedale Policlinico San Martino, Genoa, Italy. [Molinelli C, Ruelle T, Giannubilo I, Arecco L] U.O. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genoa, Italy. Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genoa, Italy. [Saura C] Servei d’Oncologia Mèdica, Vall d’Hebron Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

Source: Eur J Clin Invest
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname

Subject Terms: CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal::Antibodies, Monoclonal, Humanized, Immunoconjugates, Neutropenia, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, Pacients - Satisfacció, Medicaments antineoplàstics - Ús terapèutic, Breast Neoplasms, COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales::anticuerpos monoclonales humanizados, HEALTH CARE::Environment and Public Health::Public Health::Epidemiologic Measurements::Demography::Health Status::Quality of Life, COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::globulinas séricas::inmunoglobulinas::anticuerpos::inmunoconjugados, Ado-Trastuzumab Emtansine, Antibodies, Monoclonal, Humanized, Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos, Antineoplastic Agents, Immunological, Humans, CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Serum Globulins::Immunoglobulins::Antibodies::Immunoconjugates, ATENCIÓN DE SALUD::ambiente y salud pública::salud pública::medidas epidemiológicas::demografía::estado de salud::calidad de vida, Randomized Controlled Trials as Topic, Other subheadings::Other subheadings::Other subheadings::/drug therapy, Anticossos monoclonals - Ús terapèutic, Nausea, Trastuzumab, Thrombocytopenia, adverse events, antibody‐drug conjugate, breast cancer, quality of life, toxicity, Other subheadings::Other subheadings::Other subheadings::/adverse effects, Mama - Càncer - Tractament, Meta‐analysis, Quality of Life, Female, Camptothecin, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama, DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/39943891
http://hdl.handle.net/11351/13351
https://hdl.handle.net/11567/1249817
https://doi.org/10.1111/eci.70001

Predictability of B cell clonal persistence and immunosurveillance in breast cancer

Authors: Sammut, S-J, Galson, JD, Minter, R, Sun, B, Chin, S-F, De Mattos-Arruda, L, Finch, DK, Schätzle, S, Dias, J, Rueda, OM, Seoane, J, Osbourn, J, Caldas, C, Bashford-Rogers, RJM

Contributors: Institut Català de la Salut, [Sammut SJ] Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK. The Royal Marsden Hospital NHS Foundation Trust, London, UK. [Galson JD, Minter R] Alchemab Therapeutics, Whittlesford, UK. [Sun BO] Wellcome Centre for Human Genetics, Oxford, UK. Nuffield Department of Clinical Neuroscience, University of Oxford, Oxford, UK. [Chin SF] Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK. [De Mattos-Arruda L] IrsiCaixa, Germans Trias i Pujol University Hospital, Badalona, Spain. Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain. [Seoane J] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Institució Catalana de Recerca i Estudis Avançats (ICREA), Universitat Autònoma de Barcelona, Bellaterra, Spain. CIBERONC, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona, DSpace at Cambridge pro (8.1), Sammut, Stephen John

Source: Nat Immunol
Nature Immunology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
Institut de Recerca Germans Trias i Pujol (IGTP)
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona

Subject Terms: Resource, Monitoring, Cèl·lules B, T-Lymphocytes, Receptors, Antigen, T-Cell, Receptors, Antigen, B-Cell, Breast Neoplasms, Immunitat cel·lular, Immunoediting, Mama - Càncer, Immunologic, Monitoring, Immunologic, Antigens, Neoplasm, Receptors, Exome Sequencing, Humans, Antigens, Neoplasm Metastasis, Immunologic Surveillance, B-Lymphocytes, PHENOMENA AND PROCESSES::Immune System Phenomena::Immunity::Adaptive Immunity::Immunity, Cellular::Immunologic Surveillance, B-Cell, Immunological surveillance, T-Cell, ANATOMY::Cells::Antibody-Producing Cells::B-Lymphocytes, Clone Cells, 3. Good health, ANATOMÍA::células::células productoras de anticuerpos::linfocitos B, Clonal selection, FENÓMENOS Y PROCESOS::fenómenos del sistema inmunitario::inmunidad::inmunidad adaptativa::inmunidad celular::vigilancia inmunológica, Antigen, Neoplasm, Female, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama, DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms

File Description: application/pdf; application/zip; text/xml; Print-Electronic

Access URL: https://pubmed.ncbi.nlm.nih.gov/38698238
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=15316
https://hdl.handle.net/11351/11431
https://www.repository.cam.ac.uk/handle/1810/367953
https://doi.org/10.1038/s41590-024-01821-0

First-line therapy with palbociclib in patients with advanced HR+/HER2− breast cancer: The real-life study PALBOSPAIN

Authors: N. Martínez-Jañez, M. Bellet Ezquerra, L. M. Manso Sanchez, F. Henao Carrasco, A. Anton Torres, S. Morales, P. Tolosa Ortega, V. L. Obadia Gil, T. Sampedro, R. Andrés Conejero, L. Calvo-Martinez, E. Galve-Calvo, R. López, F. Ayala de la Pena, S. Lopez-Tarruella, B. A. Hernando Fernandez de Araguiz, L. Boronat Ruiz, T. Martos Cardenas, J. I. Chacon, F. Moreno Antón

Contributors: Institut Català de la Salut, [Martínez-Jañez N] Medical Oncology Department, Ramon y Cajal University Hospital, Hospital Ramón y Cajal, Madrid, Spain. [Bellet Ezquerra M] Medical Oncology Department, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Manso Sanchez LM] Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain. [Henao Carrasco F] Oncology, Hospital Universitario Virgen Macarena, Sevilla, Spain. [Anton Torres A] Medical Oncology Department, Hospital Universitario Miguel Servet, Zaragoza, Spain. [Morales S] Medical Oncology Department, Hospital Arnau de Vilanova - Lleida, Alpicat, Spain, Vall d'Hebron Barcelona Hospital Campus

Source: Breast Cancer Res Treat
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname

Subject Terms: Adult, Male, 0301 basic medicine, CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Protein Kinase Inhibitors, Other subheadings::Other subheadings::/therapeutic use, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, Pyridines, Receptor, ErbB-2, First-line treatment, COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::mecanismos moleculares de acción farmacológica::inhibidores enzimáticos::inhibidores de proteínas cinasas, Otros calificadores::Otros calificadores::/uso terapéutico, Breast Neoplasms, Palbociclib, Piperazines, 03 medical and health sciences, 0302 clinical medicine, Humans, Overall survival, Protein Kinase Inhibitors, Aged, Retrospective Studies, Aged, 80 and over, Original Laboratory Investigation, Other subheadings::Other subheadings::Other subheadings::/drug therapy, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome, Progression-free survival, Middle Aged, Progression-Free Survival, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento, Receptors, Estrogen, HR+/HER2−, Mama - Càncer - Tractament, Avaluació de resultats (Assistència sanitària), Advanced breast cancer, Female, Receptors, Progesterone, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama, DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms, Proteïnes quinases - Inhibidors - Ús terapèutic

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/38561577
https://hdl.handle.net/11351/11611

Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer

Authors: Harvey-Jones, E, Raghunandan, M, Robbez-Masson, L, Magraner-Pardo, L, Alaguthurai, T, Yablonovitch, A, Yen, J, Xiao, H, Brough, R, Frankum, J, Song, F, Yeung, J, Savy, T, Gulati, A, Alexander, J, Kemp, H, Starling, C, Konde, A, Marlow, R, Cheang, M, Proszek, P, Hubank, M, Cai, M, Trendell, J, Lu, R, Liccardo, R, Ravindran, N, Llop-Guevara, A, Rodriguez, O, Balmana, J, Lukashchuk, N, Dorschner, M, Drusbosky, L, Roxanis, I, Serra, V, Haider, S, Pettitt, SJ, Lord, CJ, Tutt, ANJ

Contributors: Institut Català de la Salut, [Harvey-Jones E] The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK. The Breast Cancer Now Research Unit, Guy's Hospital Cancer Centre, King's College London, UK. The City of London Cancer Research UK Centre at King's College London, UK. [Raghunandan M, Robbez-Masson L, Magraner-Pardo L] The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK. [Alaguthurai T] The Breast Cancer Now Research Unit, Guy's Hospital Cancer Centre, King's College London, UK. [Yablonovitch A] Guardant Health Inc., Redwood City, USA. [Balmaña J, Serra V] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus, Song, Feifei, Yeung, Chit Sum Jason, Cheang, Chon, Hubank, Michael, Haider, Syed, Lord, Christopher, Tutt, Andrew

Source: Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname

Subject Terms: Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, Antineoplastic Agents, Breast Neoplasms, Poly(ADP-ribose) Polymerase Inhibitors, breast cancer, Humans, platinum, PHENOMENA AND PROCESSES::Genetic Phenomena::Recombination, Genetic::Homologous Recombination, Recombinació genètica, Homologous Recombination, PARP inhibitors, Resistència als medicaments, BRCA2 Protein, FENÓMENOS Y PROCESOS::fenómenos genéticos::variación genética::mutación, drug resistance, Other subheadings::Other subheadings::Other subheadings::/drug therapy, PHENOMENA AND PROCESSES::Physiological Phenomena::Pharmacological and Toxicological Phenomena::Pharmacological Phenomena::Drug Resistance, liquid biopsy, BRCA1 Protein, FENÓMENOS Y PROCESOS::fenómenos genéticos::recombinación genética::recombinación homóloga, Anomalies cromosòmiques, FENÓMENOS Y PROCESOS::fenómenos fisiológicos::fenómenos farmacológicos y toxicológicos::fenómenos farmacológicos::resistencia a medicamentos, homologous recombination deficiency, PHENOMENA AND PROCESSES::Genetic Phenomena::Genetic Variation::Mutation, Mama - Càncer - Tractament, Mutation, Mama - Càncer - Aspectes genètics, Female, Tumor Suppressor p53-Binding Protein 1, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama, DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms

File Description: application/pdf; Print-Electronic

Access URL: https://pubmed.ncbi.nlm.nih.gov/38244928
https://hdl.handle.net/11351/11312

Eina de suport en el diagnòstic ecogràfic per a la classificació de nòduls mamaris

Contributors: Departament de Salut

Source: Scientia

Subject Terms: Càncer - Tractament - Innovacions tecnològiques, HEALTH CARE::Health Care Economics and Organizations::Technology Assessment, Biomedical, ATENCIÓN DE SALUD::economía y organizaciones para la atención de la salud::evaluación de tecnologías biomédicas, Mama - Càncer - Diagnòstic, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama, DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms

File Description: application/pdf

Access URL: http://hdl.handle.net/11351/13243

Machine learning-based spatial characterization of tumor-immune microenvironment in the EORTC 10994/BIG 1-00 early breast cancer trial

Authors: Ioannis Zerdes, Alexios Matikas, Artur Mezheyeuski, Georgios Manikis, Balazs Acs, Hemming Johansson, Ceren Boyaci, Caroline Boman, Coralie Poncet, Michail Ignatiadis, Yalai Bai, David L. Rimm, David Cameron, Hervé Bonnefoi, Jonas Bergh, Gaetan MacGrogan, Theodoros Foukakis

Contributors: Institut Català de la Salut, [Zerdes I] Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. Theme Cancer, Karolinska Comprehensive Cancer Center and University Hospital, Stockholm, Sweden. [Matikas A] Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. Breast Center, Theme Cancer, Karolinska Comprehensive Cancer Center and University Hospital, Stockholm, Sweden. [Mezheyeuski A] Department of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden. 5 Molecular Oncology Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Manikis G] Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. Computational BioMedicine Laboratory (CBML), Foundation for Research and Technology-Hellas (FORTH), Heraklion, Greece. [Acs B] Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. Department of Clinical Pathology and Cancer Diagnostics, Karolinska University Hospital, Stockholm, Sweden. [Johansson H] Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden, Vall d'Hebron Barcelona Hospital Campus

Source: NPJ Breast Cancer
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname
npj Breast Cancer, Vol 11, Iss 1, Pp 1-12 (2025)

Subject Terms: Cancer och onkologi, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, ANATOMY::Cells::Blood Cells::Leukocytes::Leukocytes, Mononuclear::Lymphocytes::Lymphocytes, Tumor-Infiltrating, ANATOMÍA::células::células sanguíneas::leucocitos::leucocitos mononucleares::linfocitos::linfocitos infiltrantes de tumor, Limfòcits, Article, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Combined Modality Therapy::Neoadjuvant Therapy, Otros calificadores::Otros calificadores::Otros calificadores::/inmunología, Cancer and Oncology, Mama - Càncer - Tractament, Aprenentatge automàtic, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::tratamiento combinado::tratamiento neoadyuvante, PHENOMENA AND PROCESSES::Mathematical Concepts::Algorithms::Artificial Intelligence::Machine Learning, Cèl·lules canceroses, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis, FENÓMENOS Y PROCESOS::conceptos matemáticos::algoritmos::inteligencia artificial::aprendizaje automático, Mama - Càncer - Aspectes immunològics, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico, Other subheadings::Other subheadings::Other subheadings::/immunology, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama, RC254-282, DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/40055382
http://hdl.handle.net/11351/12970
https://doaj.org/article/d8fab5fc752243b386619a06b7752b40
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-553358

Swarm learning with weak supervision enables automatic breast cancer detection in magnetic resonance imaging

Authors: Oliver Lester Saldanha, Jiefu Zhu, Gustav Müller-Franzes, Zunamys I. Carrero, Nicholas R. Payne, Lorena Escudero Sánchez, Paul Christophe Varoutas, Sreenath Kyathanahally, Narmin Ghaffari Laleh, Kevin Pfeiffer, Marta Ligero, Jakob Behner, Kamarul A. Abdullah, Georgios Apostolakos, Chrysafoula Kolofousi, Antri Kleanthous, Michail Kalogeropoulos, Cristina Rossi, Sylwia Nowakowska, Alexandra Athanasiou, Raquel Perez-Lopez, Ritse Mann, Wouter Veldhuis, Julia Camps, Volkmar Schulz, Markus Wenzel, Sergey Morozov, Alexander Ciritsis, Christiane Kuhl, Fiona J. Gilbert, Daniel Truhn, Jakob Nikolas Kather

Contributors: Institut Català de la Salut, [Saldanha OL] Else Kroener Fresenius Center for Digital Health, Medical Faculty Carl Gustav Carus, Technical University Dresden, Dresden, Germany. Department of Diagnostic and Interventional Radiology, University Hospital RWTH Aachen, Aachen, Germany. [Zhu J] Else Kroener Fresenius Center for Digital Health, Medical Faculty Carl Gustav Carus, Technical University Dresden, Dresden, Germany. [Müller-Franzes G, Carrero ZI] Department of Diagnostic and Interventional Radiology, University Hospital RWTH Aachen, Aachen, Germany. [Payn NR] Department of Radiology, Clinical School, Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, UK. [Escudero Sánchez L] Department of Radiology, Clinical School, Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, UK. Cancer Research UK Cambridge Centre, Cambridge, UK. [Perez-Lopez R] Radiomics Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus, MS Radiologie, Cancer, Circulatory Health, Apollo - University of Cambridge Repository

Source: Commun Med (Lond)
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname
Communications Medicine, Vol 5, Iss 1, Pp 1-12 (2025)
Communications Medicine, 5, 1

Subject Terms: Epidemiology, Medicine (miscellaneous), TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::técnicas y procedimientos diagnósticos::diagnóstico por imagen::tomografía::imagen por resonancia magnética, 32 Biomedical and Clinical Sciences, Bioengineering, Assessment and Diagnosis, Article, 46 Information and Computing Sciences, Breast Cancer, Medical Imaging - Radboud University Medical Center, FENÓMENOS Y PROCESOS::conceptos matemáticos::algoritmos::inteligencia artificial::aprendizaje automático::aprendizaje profundo, Machine Learning and Artificial Intelligence, Internal Medicine, Cancer, PHENOMENA AND PROCESSES::Mathematical Concepts::Algorithms::Artificial Intelligence::Machine Learning::Deep Learning, Intel·ligència artificial - Aplicacions a la medicina, Data Science, Public Health, Environmental and Occupational Health, Otros calificadores::Otros calificadores::Otros calificadores::/diagnóstico por imagen, Other subheadings::Other subheadings::Other subheadings::/diagnostic imaging, 3211 Oncology and Carcinogenesis, Mama - Càncer - Imatgeria per ressonància magnètica, Networking and Information Technology R&D (NITRD), Biomedical Imaging, Women's Health, Medicine, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Diagnostic Techniques and Procedures::Diagnostic Imaging::Tomography::Magnetic Resonance Imaging, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama, DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms, Aprenentatge profund

File Description: application/pdf; application/zip; text/xml

Access URL: https://pubmed.ncbi.nlm.nih.gov/39915630
http://hdl.handle.net/11351/12859
https://doaj.org/article/a1bcf5ae3c6b4dc7a9c39931cc3a78b4
https://hdl.handle.net/https://repository.ubn.ru.nl/handle/2066/317474
https://dspace.library.uu.nl/handle/1874/460712
https://repository.ubn.ru.nl//bitstream/handle/2066/317474/317474.pdf
https://hdl.handle.net/2066/317474

Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13])

Authors: A. DeMichele, A. C. Dueck, D. Hlauschek, M. Martin, H. Burstein, G. Pfeiler, N. Zdenkowski, A. Wolff, M. Bellet-Ezquerra, E. Winer, M. Balic, K. Miller, M. Colleoni, D. Lake, G. Rubovsky, D. Cameron, J. Balko, C. F. Singer, Z. Nowecki, H. Iwata, N. Wolmark, K. A. Parraga, H. Rugo, G. G. Steger, T. Traina, G. Werutsky, D. Czajkowska, O. Metzger, S. El-Abed, K. P. Theall, R. D. Lu, P. O’Brien, C. Fesl, E. Mayer, M. Gnant

Contributors: Institut Català de la Salut, [DeMichele A] Department of Hematology and Oncology, Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, USA. ECOG-ACRIN Cancer Research Group, Philadelphia, PA, USA. [Dueck AC] Division of Clinical Trials and Biostatistics, Department of Quantitative Health Sciences, Mayo Clinic, Phoenix, AZ, USA. [Hlauschek D] Austrian Breast & Colorectal Cancer Study Group (ABCSG), Vienna, Austria. [Martin M] Gregorio Maranon, Madrid, Spain. [Burstein H] Dana-Farber Cancer Institute, Boston, MA, USA. Alliance Foundation Trials (AFT) LLC, Boston, MA, USA. [Pfeiler G] Medical University of Vienna, Vienna, Austria. [Bellet Ezquerra M] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

Source: Breast Cancer Res
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname
Breast Cancer Research, Vol 27, Iss 1, Pp 1-8 (2025)

Subject Terms: Adult, Mama - Càncer - Prognosi, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada, Pyridines, Receptor, ErbB-2, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Neoplasm Staging, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::estadificación de neoplasias, Mama - Càncer - Recaiguda, Breast Neoplasms, CDK4/6 inhibitor, Quimioteràpia combinada, Piperazines, DISEASES::Neoplasms::Neoplastic Processes::Neoplasm Recurrence, Local, Antineoplastic Combined Chemotherapy Protocols, Humans, Stage II breast cancer, Adjuvant, RC254-282, Neoplasm Staging, Aged, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome, Research, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Middle Aged, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento, Treatment Outcome, Chemotherapy, Adjuvant, Mama - Càncer - Tractament, ENFERMEDADES::neoplasias::procesos neoplásicos::recurrencia neoplásica local, Avaluació de resultats (Assistència sanitària), Female, Neoplasm Recurrence, Local, Endocrine, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama, DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/39849600
http://hdl.handle.net/11351/12772
https://doaj.org/article/054e50e8fd924275b24a583124a5d13f

Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01)

Authors: C. Saura, S. Modi, I. Krop, Y.H. Park, S.-B. Kim, K. Tamura, H. Iwata, J. Tsurutani, J. Sohn, E. Mathias, Y. Liu, J. Cathcart, J. Singh, T. Yamashita

Contributors: Institut Català de la Salut, [Saura C] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Modi S] Memorial Sloan Kettering Cancer Center, New York, USA. [Krop I] Yale Cancer Center, New Haven, USA. [Park YH] Samsung Medical Center, Seoul. [Kim SB] Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. [Tamura K] Shimane University Hospital, Izumo , Japan, Vall d'Hebron Barcelona Hospital Campus

Source: Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname

Subject Terms: 0301 basic medicine, CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal::Antibodies, Monoclonal, Humanized, Other subheadings::Other subheadings::Other subheadings::/drug therapy, Immunoconjugates, Anticossos monoclonals - Ús terapèutic, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, Receptor, ErbB-2, Breast Neoplasms, COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales::anticuerpos monoclonales humanizados, Trastuzumab, COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::globulinas séricas::inmunoglobulinas::anticuerpos::inmunoconjugados, Antibodies, Monoclonal, Humanized, Ado-Trastuzumab Emtansine, 3. Good health, 03 medical and health sciences, 0302 clinical medicine, Mama - Càncer - Tractament, Humans, CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Serum Globulins::Immunoglobulins::Antibodies::Immunoconjugates, Female, Camptothecin, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama, DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/38092229
https://hdl.handle.net/11351/11152